Effect of a Multi-strain Probiotic on Recurrent Vulvovaginal Candidiasis
← catalyst calendarSponsored by The Archer-Daniels-Midland Company (industry) · ADM — their whole pipeline →. With Vedic Lifesciences Pvt. Ltd..
Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Prevention
Enrollment
126estimated
Sites
6
Country
India
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-15 | actual | When the study began enrolling |
| Primary completion | Jul 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2025 | estimated | The whole study's end, after follow-up |
| First posted | 2024-06-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-11-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Vulvovaginal Candidiasis
Interventions
- Dietary supplement: Probiotic
- Dietary supplement: Placebo
Primary outcome
what the primary-completion date above is the date OFIncidence of culture-confirmed VVC recurrence between baseline and day 180 as compared to placebo.
measured Day 0, Day 180
Permalink · ADM's whole pipeline · Catalyst calendar · Every registered study · What changed